Upstream Bio Income Statement (2023-2025) | UPB

Income Statement Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.62M0.45M0.64M0.51M0.61M0.61M0.57M0.94M0.68M
Gross Profit 0.29M-0.91M-1.57M-2.15M-1.56M-9.06M-1.86M
Operating items
Research & Development 7.79M11.55M11.69M14.07M15.43M21.77M25.80M37.87M32.98M
Selling, General & Administrative 2.22M3.23M3.96M3.98M4.07M5.16M6.78M7.42M5.54M
Restructuring Costs 0.46M0.33M0.35M0.84M1.05M1.25M0.89M
Other Operating Expenses -0.46M-0.33M-0.35M-0.84M-1.05M-1.25M-0.89M
Operating Expenses 10.01M14.78M15.65M18.05M19.50M26.93M32.58M45.28M38.52M
Operating Income -9.39M-14.33M-15.01M-17.54M-18.89M-26.32M-32.01M-44.35M-37.83M
EBIT -9.39M-14.33M-15.01M-17.54M-18.89M-26.32M-32.01M-44.35M-37.83M
Non-operating items
Interest & Investment Income 1.53M1.52M1.27M2.88M2.90M5.08M4.74M4.43M4.11M
Non Operating Income 6.28M2.50M4.12M2.86M2.90M5.08M4.74M4.38M4.09M
Net income details
EBT -7.86M-12.81M-13.75M-14.66M-15.99M-21.24M-27.27M-39.92M-33.73M
Profit After Tax -3.10M-11.83M-10.90M-14.68M-15.99M-21.21M-27.30M-39.97M-33.75M
Income from Continuing Operations -7.86M-12.81M-13.75M-14.66M-15.99M-21.24M-27.27M-39.92M-33.73M
Consolidated Net Income -7.86M-12.81M-13.75M-14.66M-15.99M-21.24M-27.27M-39.92M-33.73M
Income towards Parent Company -7.86M-12.81M-13.75M-14.66M-15.99M-21.24M-27.27M-39.92M-33.73M
Preferred Dividend Payments 3.15M3.15M3.12M4.88M5.04M0.55M
Net Income towards Common Stockholders -6.25M-14.98M-14.01M-19.56M-21.03M-21.79M-27.27M-39.97M-33.75M
Additional items
EPS (Basic) -2.11-5.05-4.68-6.50-6.9612.57-0.51-0.74-0.63
EPS (Weighted Average and Diluted) -2.11-5.05-4.68-6.50-6.9612.57-0.51-0.74-0.63
Shares Outstanding (Weighted Average) 36.34M36.34M48.84M53.60M53.60M53.64M53.79M53.91M
Shares Outstanding (Diluted Average) 2.96M2.95M3.00M3.01M3.02M13.68M53.62M53.77M53.93M
EBITDA -9.39M-14.33M-15.01M-17.54M-18.89M-26.32M-32.01M-44.35M-37.83M
Shares Outstanding 2.97M2.99M3.00M3.02M3.03M53.60M53.64M53.80M54.00M